These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35473773)

  • 1. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B].
    Hong YM; Yoon KT
    Korean J Gastroenterol; 2022 Apr; 79(4):156-160. PubMed ID: 35473773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend.
    Wong GL
    Clin Mol Hepatol; 2018 Jun; 24(2):108-113. PubMed ID: 29353469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1762-9. PubMed ID: 23808759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unresolved issues of immune tolerance in chronic hepatitis B.
    Lee HW; Chan HL
    J Gastroenterol; 2020 Apr; 55(4):383-389. PubMed ID: 32016713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Yan JY; Li ZQ; Yu ZJ; Kan QC
    J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of chronic hepatitis B in severe liver disease.
    Fung J; Lai CL; Yuen MF
    World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons to consider early treatment in chronic hepatitis B patients.
    Koffas A; Petersen J; Kennedy PT
    Antiviral Res; 2020 May; 177():104783. PubMed ID: 32217150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
    Chu CM
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Okada M; Enomoto M; Kawada N; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBV: Do I treat my immunotolerant patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2016 Jan; 36 Suppl 1():93-9. PubMed ID: 26725904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B in children: complexities in management.
    Kerkar N
    Pediatr Transplant; 2005 Oct; 9(5):685-91. PubMed ID: 16176431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach to the patient with chronic hepatitis B and decompensated cirrhosis.
    Shiffman ML
    Liver Int; 2020 Feb; 40 Suppl 1():22-26. PubMed ID: 32077612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
    Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
    J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.
    Jeon MY; Kim BK; Lee JS; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Clin Mol Hepatol; 2021 Apr; 27(2):295-304. PubMed ID: 33317247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating Immune-tolerant Hepatitis B.
    Tseng TC; Kao JH
    J Viral Hepat; 2015 Feb; 22(2):77-84. PubMed ID: 25424771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.